Research and analysis

Ethylbromazolam: review of the evidence on its use and harms

The report reviews the evidence on the use and harms of the novel benzodiazepine ethylbromazolam and recommends control under the Misuse of Drugs Act 1971.

• From: Advisory Council on the Misuse of Drugs
• Published: 14 April 2026

Documents

Ethylbromazolam: a review of the evidence on its use and harms (accessible version)

HTML

Ethylbromazolam: a review of the evidence on its use and harms

PDF, 378 KB, 20 pages

This file may not be suitable for users of assistive technology.

Request an accessible format.

If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email alternativeformats@homeoffice.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Cover letter from ACMD report on ethylbromazolam (accessible version)

HTML

Cover letter from ACMD report on ethylbromazolam

PDF, 140 KB, 2 pages

This file may not be suitable for users of assistive technology.

Request an accessible format.

If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email alternativeformats@homeoffice.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Details

Based on the review of the currently available evidence, the Advisory Council on the Misuse of Drugs (ACMD) recommends:

• making ethylbromazolam a Class C drug
• adding ethylbromazolam to Schedule 1 of the Misuse of Drugs Regulations 2001

Published 14 April 2026